A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To present an updated, comprehensive review on clinical and pre-clinical studies on agomelatine. METHOD: A MEDLINE, Psycinfo and Web of Science search (1966-May 2009) was performed using the following keywords: agomelatine, melatonin, S20098, efficacy, safety, adverse effect, pharmacokinetic, pharmacodynamic, major depressive disorder, bipolar disorder, Seasonal Affective Disorder (SAD), Alzheimer, ADHD, Generalized Anxiety Disorder (GAD), Panic Disorder (PD), Obsessive-Compulsive Disorder (OCD), anxiety disorders and mood disorder. STUDY COLLECTION AND DATA EXTRACTION: All articles in English identified by the data sources were evaluated. Randomized, controlled clinical trials involving humans were prioritized in the review. The physiological bases of melatonergic transmission were also examined to deepen the clinical comprehension of agomelatine' melatonergic modulation. DATA SYNTHESIS: Agomelatine, a melatonergic analogue drug acting as MT(1)/MT(2) agonist and 5-HT(2C) antagonist, has been reported to be an effective antidepressant therapy. CONCLUSIONS: Although a bias in properly assessing the "sleep core" of depression may still exist with current screening instruments, therefore making difficult to compare agomelatine' efficacy to other antidepressant ones, comparative studies showed agomelatine to be an intriguing option for depression and, potentially, for other therapeutic targets as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“Among psychiatric illnesses, BPD is second only to unipolar depression as a cause of global disability [114] and may largely go underdiagnosed [115].”
BackgroundThe Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243 · cited 1×
“Symptomatic patients with BP-I disorder experience depressive symptoms three to four times more than manic symptoms [116, 117] and symptomatic patients with BP-II disorder experience depressive symptoms approximately 39 times more than hypomanic ones [118].”
BackgroundAnderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940 · cited 1×
“By avoiding 5-HT2A stimulation, agomelatine shows a more favorable side-effect profile compared SSRIs, concerning sexual functioning, weight-gain (drugs blocking the 5-HT2C and histamine receptors are usually associated with weight-gain although 5-HT2C per se shouldn’t be necessarily associated with this effect) and G…”
BackgroundEhlers, C. L. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800340076012 · Cited by 707 · cited 1×
“articulated the hypothesis concerning the way in which stressful life events that disrupt an individual’s normal routines (“social zeitgebers”) could initiate a cascade that – in vulnerable subjects – might lead to an episode of depression or mania [113].”
BackgroundSelective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Castrén, E. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1629 · Cited by 563
Post, R. M., Denicoff, K. D., Leverich, G. S., Altshuler, L. L., Frye, M. A., Suppes, T. M., Rush, A. J., Keck, P. E., McElroy, S. L., Luckenbaugh, D. A., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0610 · Cited by 418 · cited 1×
“Symptomatic patients with BP-I disorder experience depressive symptoms three to four times more than manic symptoms [116, 117] and symptomatic patients with BP-II disorder experience depressive symptoms approximately 39 times more than hypomanic ones [118].”
BackgroundSouêtre, E., Salvati, E., Belugou, J.-L., Pringuey, D., Candito, M., Krebs, B., Ardisson, J.-L., & Darcourt, G. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90207-2 · Cited by 396 · cited 1×
“Yet, measurement of melatonin levels has shown significantly lower levels in unipolar and bipolar depressed patients [128].”
BackgroundMelatonin, human aging, and age-related diseases
Karasek, M. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.04.012 · Cited by 380 · cited 1×
“until around age of 40 before it fall further [65, 66].”
BackgroundIs bipolar disorder still underdiagnosed? Are antidepressants overutilized?
Ghaemi, S. N., Sachs, G. S., M. Chiou, A., Pandurangi, A. K., & Goodwin, F. K. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00076-7 · Cited by 376
Melatonin Prevents Death of Neuroblastoma Cells Exposed to the Alzheimer Amyloid Peptide
Pappolla, M. A., Sos, M., Omar, R. A., Bick, R. J., Hickson-Bick, D. L. M., Reiter, R. J., Efthimiopoulos, S., & Robakis, N. K. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01683.1997 · Cited by 359 · cited 2×
“Melatonin also inhibits the aggregation of the amyloid beta protein into neurotoxic micro-aggregates which seem to underlie the neurotoxicity of this protein, causing neuronal death and formation of neurofibrillary tangles, which are the other neuropathological landmark of Alzheimer's disease [90].”
BackgroundJohansson, C., Willeit, M., Smedh, C., Ekholm, J., Paunio, T., Kieseppä, T., Lichtermann, D., Praschak-Rieder, N., Neumeister, A., Nilsson, L.-G., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300121 · Cited by 341 · cited 7×
“MDD with seasonal patterns (MDDSP) is clinically characterized by depressed mood occurring at almost the same time every year since the disorder is first experienced [106].”
BackgroundInfluentialGoodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340
Kalsbeek, A., La Fleur, S., Van Heijningen, C., & Buijs, R. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5328-03.2004 · Cited by 244
Shirayama, Y., & Chaki, S. (2006) · Current Neuropharmacology · doi:10.2174/157015906778520773 · Cited by 225 · cited 1×
“However, microdialysis studies reported dopamine levels in the nucleus Accumbens (ACn), a structure proven to be involved in course of depression in rats [50] and the striatum to be unaffected by agomelatine [51] whereas it remarkably rises at the prefrontal cortex of rats [52, 53].”
BackgroundMontgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Cellular and molecular mechanisms in the long-term action of antidepressants.
Racagni, G., & Popoli, M. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/gracagni · Cited by 192 · cited 5×
“They include the NK-1 receptors antagonists, CRF1 antagonists and the glutamatergic agents (NMDA blockers, AMPAkines, mGlu modulators, riluzole, lamotrigine) [3].”
BackgroundInfluentialMichelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181 · cited 1×
“SSRIs still represent the most currently prescribed antidepressant class of drugs, nevertheless their efficacy has been questioned [9-16].”
BackgroundLeproult, R., Van Onderbergen, A., L’Hermite‐Balériaux, M., Van Cauter, E., & Copinschi, G. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02341.x · Cited by 167 · cited 1×
“MT and its receptor agonists, including agomelatine, correct age-related changes in circadian response to environmental stimuli in rodents, and could prove to be useful in treating/preventing or delaying disturbances of circadian rhythmicity and/or sleep in older people [67, 68].”
BackgroundMendlewicz, J. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970802503086 · Cited by 143 · cited 1×
“Anyway, since studies demonstrated possible persistent sleep changes in the remission phase of depression, it is unclear whether it is a causative factor or part of the clinical picture [22].”
BackgroundHindmarch, I., Kimber, S., & Cockle, S. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00001 · Cited by 84
Ethnicity, sleep, mood, and illumination in postmenopausal women
Kripke, D. F., Jean-Louis, G., Elliott, J. A., Klauber, M. R., Rex, K. M., Tuunainen, A., & Langer, R. D. (2004) · BMC Psychiatry · doi:10.1186/1471-244x-4-8 · Cited by 69
Tuma, J., Strubbe, J. H., Mocaër, E., & Koolhaas, J. M. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.02.004 · Cited by 60 · cited 2×
“…differs from that of benzodiazepines from which it may also be distinguished by its con- trasting influence on cortico- limbic monoaminergic pathways Tuma et al. (2005) Animal model (murine) Animal model of anxiety (social defeat) SCN-lesioned and non lesioned rats, subjected at a social…”
BackgroundThe prevalence of seasonal affective disorder (SAD) in Greenland is related to latitude.
Kegel, M., Dam, H., Ali, F., & Bjerregaard, P. (2009) · Nordic Journal of Psychiatry · doi:10.1080/08039480902799040 · Cited by 47
Tint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087488 · Cited by 13
Cited by
Circadian rhythms and depression: Human psychopathology and animal models
Kronfeld-Schor, N., & Einat, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.020 · Cited by 166
Role of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Fornaro, M., McCarthy, M. J., De Berardis, D., Pasquale, D., Martino, Colicchio, Cattaneo, D'Angelo, Fornaro, P., & Tabaton (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41557 · Cited by 67
“This could be in marked contrast to standard antidepressants, with their propensity toward causing weight gain via serotonergic stimulation of 5-HT2A receptors rather than selective antagonism of 5-HT2C.(9,51,76,77) It will be of interest in the future to determine whether agomelatine affects excessive or atypical eat…”
Self-citationAgomelatine for the treatment of generalized anxiety disorder
Buoli, M., Grassi, S., Serati, M., & Altamura, A. C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1359257 · Cited by 61
Mental Health of Quarantine and Isolation
Huremović, D. (2019) · Psychiatry of Pandemics · doi:10.1007/978-3-030-15346-5_9 · Cited by 50
Metadata
- Authors
- Fornaro, M., Prestia, D., Colicchio, S., & Perugi, G.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-09-01
- Volume
- 8
- Issue
- 3
- Pages
- 287-304
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2043091334
- Cited by
- 119
- References
- 26
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.